BR112018004454A2 - nova subpopulação de tregs cd8+cd45rcbaixo e seu uso - Google Patents
nova subpopulação de tregs cd8+cd45rcbaixo e seu usoInfo
- Publication number
- BR112018004454A2 BR112018004454A2 BR112018004454A BR112018004454A BR112018004454A2 BR 112018004454 A2 BR112018004454 A2 BR 112018004454A2 BR 112018004454 A BR112018004454 A BR 112018004454A BR 112018004454 A BR112018004454 A BR 112018004454A BR 112018004454 A2 BR112018004454 A2 BR 112018004454A2
- Authority
- BR
- Brazil
- Prior art keywords
- cd45rc
- sub
- new
- population below
- population
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306366 | 2015-09-07 | ||
| PCT/EP2016/070991 WO2017042170A1 (en) | 2015-09-07 | 2016-09-06 | A new subpopulation of cd8+cd45rclow tregs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018004454A2 true BR112018004454A2 (pt) | 2018-09-25 |
Family
ID=54196910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018004454A BR112018004454A2 (pt) | 2015-09-07 | 2016-09-06 | nova subpopulação de tregs cd8+cd45rcbaixo e seu uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180251731A1 (https=) |
| EP (1) | EP3347452B1 (https=) |
| JP (2) | JP2018527932A (https=) |
| KR (1) | KR102768442B1 (https=) |
| CN (1) | CN108291203A (https=) |
| AU (1) | AU2016318762B2 (https=) |
| BR (1) | BR112018004454A2 (https=) |
| CA (1) | CA2997646C (https=) |
| ES (1) | ES2890818T3 (https=) |
| IL (1) | IL257891B (https=) |
| MX (1) | MX390494B (https=) |
| WO (1) | WO2017042170A1 (https=) |
| ZA (1) | ZA201801265B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042179A1 (en) * | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| EP4417210A1 (en) | 2017-03-15 | 2024-08-21 | Orca Biosystems, Inc. | Compositions and methods for hematopoietic stem cell transplants |
| EP3652306A1 (en) | 2017-07-13 | 2020-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs |
| WO2019141774A1 (en) * | 2018-01-19 | 2019-07-25 | Miltenyi Biotec Gmbh | Regulatory t cell expressing a chimeric antigen receptor |
| EP3749334B1 (en) | 2018-02-08 | 2024-12-11 | The Board of Trustees of the Leland Stanford Junior University | Allogenic hematopoietic stem cell transplantation |
| CN111936180B (zh) * | 2018-03-14 | 2024-04-05 | 热动力医疗公司 | 浮力激活细胞分选(bacs)兼容的激活/转导系统和方法 |
| AU2019378883A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for T cell delivery |
| EP3894543A1 (en) * | 2018-12-14 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs |
| MX2021013227A (es) * | 2019-04-30 | 2022-01-06 | Univ California | Expansion ex-vivo sin microesferas de celulas t reguladoras humanas. |
| AU2020327949A1 (en) * | 2019-08-14 | 2022-03-03 | The Regents Of The University Of California | CAR-T cells specific for modified proteins in extracellular spaces |
| WO2024028486A1 (en) * | 2022-08-04 | 2024-02-08 | Nantes Universite | In vitro method for obtaining clinical-grade cd8+ cd45rclow/- regulatory t cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001253400B2 (en) * | 2000-04-11 | 2007-03-01 | University Of Southern California | A method to prevent graft rejection using tgf-beta to induce t suppressor cells |
| EP2126054B1 (en) * | 2007-01-31 | 2016-07-06 | Yeda Research And Development Company Limited | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| ES2702676T3 (es) * | 2014-04-01 | 2019-03-04 | Inst Nat Sante Rech Med | Péptido de donante aislado derivado de MHC y usos del mismo |
| US10155025B2 (en) * | 2014-07-17 | 2018-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34 |
-
2016
- 2016-09-06 JP JP2018511706A patent/JP2018527932A/ja active Pending
- 2016-09-06 AU AU2016318762A patent/AU2016318762B2/en active Active
- 2016-09-06 CN CN201680064881.0A patent/CN108291203A/zh active Pending
- 2016-09-06 US US15/758,139 patent/US20180251731A1/en not_active Abandoned
- 2016-09-06 CA CA2997646A patent/CA2997646C/en active Active
- 2016-09-06 KR KR1020187009677A patent/KR102768442B1/ko active Active
- 2016-09-06 WO PCT/EP2016/070991 patent/WO2017042170A1/en not_active Ceased
- 2016-09-06 MX MX2018002849A patent/MX390494B/es unknown
- 2016-09-06 ES ES16769882T patent/ES2890818T3/es active Active
- 2016-09-06 EP EP16769882.8A patent/EP3347452B1/en active Active
- 2016-09-06 BR BR112018004454A patent/BR112018004454A2/pt not_active Application Discontinuation
-
2018
- 2018-02-23 ZA ZA2018/01265A patent/ZA201801265B/en unknown
- 2018-03-05 IL IL257891A patent/IL257891B/en active IP Right Grant
-
2021
- 2021-08-18 JP JP2021133065A patent/JP7254128B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016318762A1 (en) | 2018-03-22 |
| RU2766691C2 (ru) | 2022-03-15 |
| JP7254128B2 (ja) | 2023-04-07 |
| CN108291203A (zh) | 2018-07-17 |
| MX390494B (es) | 2025-03-20 |
| US20180251731A1 (en) | 2018-09-06 |
| IL257891A (en) | 2018-05-31 |
| KR102768442B1 (ko) | 2025-02-17 |
| RU2018107363A (ru) | 2019-10-09 |
| ZA201801265B (en) | 2022-08-31 |
| IL257891B (en) | 2020-09-30 |
| ES2890818T3 (es) | 2022-01-24 |
| JP2018527932A (ja) | 2018-09-27 |
| WO2017042170A1 (en) | 2017-03-16 |
| EP3347452A1 (en) | 2018-07-18 |
| NZ740225A (en) | 2025-05-30 |
| CA2997646A1 (en) | 2017-03-16 |
| EP3347452B1 (en) | 2021-06-23 |
| MX2018002849A (es) | 2018-09-05 |
| JP2021183631A (ja) | 2021-12-02 |
| AU2016318762B2 (en) | 2022-03-31 |
| RU2018107363A3 (https=) | 2020-02-27 |
| CA2997646C (en) | 2024-04-23 |
| KR20180054663A (ko) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018004454A2 (pt) | nova subpopulação de tregs cd8+cd45rcbaixo e seu uso | |
| MX2016013963A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| CO2018003477A2 (es) | Anticuerpos anti-pd1 y métodos de uso | |
| MX2019000180A (es) | Composiciones de células t para la inmunoterapia. | |
| MX2022013540A (es) | Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica. | |
| CL2017003023A1 (es) | Anticuerpos anti-ctla-4 y métodos de uso de los mismos. | |
| CL2018000490A1 (es) | Anticuerpos anti-pd1 y sus métodos de uso | |
| MX389827B (es) | Composición para expandir in vitro linfocitos que tiene interleucina 2 (il-2), interleucina 15 (il-15) e interleucina 21 (il-21). | |
| IL248451B (en) | Methods for the isolation, culture and genetic engineering of immune cell populations for stress therapy | |
| MX2017012616A (es) | Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y metodos para usar los mismos. | |
| MX391171B (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| BR112017017886A2 (pt) | gerando populações de células endoteliais arteriais | |
| MX2016016076A (es) | Composiciones de celulas t mejoradas. | |
| MX2016015944A (es) | Metodos para cosechar cultivos de celulas de mamifero. | |
| PH12017502255A1 (en) | Nrf2 regulators | |
| MX2020003515A (es) | Laminados elasticos con elasticos curvos y metodos para la fabricacion. | |
| CO2018001756A2 (es) | Concentrados en suspensión aceitosa con baja separación gravimétrica y baja viscosidad | |
| BR112016027196A2 (pt) | cepa bacteriana gram-negativa recombinante, vetor, método para liberar uma proteína heteróloga em uma célula eucariótica, método para purificar uma proteína heteróloga e uso de uma cepa bacteriana gram-negativa recombinante | |
| BR112016029558A2 (pt) | terapia de células-tronco em patologias endometriais | |
| NI201600127A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA. | |
| MX2017003903A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
| AR112877A1 (es) | Célula de streptococcus thermophilus (st) para preparar, por ejemplo, queso mozzarella | |
| MX2022003399A (es) | Metodo basado en celulas para determinar la potencia de la defibrotida. | |
| BR112016026905A8 (pt) | inibidores de nampt, seu uso e método para determinar sua presença, composição farmacêutica, kit, e método para inibir diferenciação de célula b em células plasmáticas | |
| CL2018001138A1 (es) | Un método ex vivo para probar la respuesta celular de las poblaciones de células primarias a una droga o combinación de drogas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES (FR) ; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; NANTES UNIVERSITE (FR) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |